The mood around the BIO-Europe conference in Munich in November was positive as people in the biotech world, or at least 5,500 of them, gathered to talk shop at over 30,000 partnering meetings. However once again, finance (or the lack of it) dominated many of the discussions heard around the Bavarian capital.
Similar views were aired a few days later at London Life Sciences Week which, as well as the Jefferies Healthcare...